Corporate News Report – Biophytis Stock Performance
During the trading session that closed at 01:11 AM Central Europe on Thursday 22 October 2026, Biophytis (ticker ALBPS.PA) experienced a significant decline, falling by 14.94 %. At the close, the share price stood at EUR 0.03, a steep drop from its previous levels. The current outstanding share count is 353.2 million, giving the company a market capitalisation of EUR 11.5 million. In the most recent 24‑hour window, trading volume reached roughly EUR 1.3 million, indicating moderate liquidity relative to the size of the market.
Historical Context
Since the close of the previous month, the share price has fallen an additional 31.43 %, underscoring a broader downward trend. The 200‑day simple moving average sits at EUR 0.04, suggesting that the current price lies just below a long‑term average. The peak of the past year was EUR 0.16 on 17 August 2026, while the trough fell to EUR 0.00 on 31 July 2026, marking a year‑long volatility range of EUR 0.16.
Comparative Performance of Peer Stocks
| Stock | 24‑hour Performance | Current Price (EUR) | Market Capitalisation (EUR mn) | P/E Ratio |
|---|---|---|---|---|
| Integritas Viager (MLVIE.PA) | 0 % | 120 | 12.5 | — |
| Soditech Ingenierie (ALSEC.PA) | +3.27 % | 5.78 | 12.5 | 5.44 |
| Stradim‑espace Finances (ALSAS.PA) | –4.86 % | 3.52 | 12.7 | 7.48 |
| Mg (ALMGI.PA) | –5.88 % | 2.24 | 12.3 | 66.85 |
| Hydrogen Refueling (ALHRS.PA) | –4.55 % | 0.65 | 13.1 | — |
While Biophytis suffered a sharp decline, its peers exhibited mixed results. Soditech Ingenierie posted a modest gain, whereas Mg and Hydrogen Refueling endured similar negative movements. Notably, Mg’s price‑to‑earnings ratio of 66.85 reflects a valuation far above its peers, potentially signalling overvaluation or heightened expectations.
Company Overview
Biophytis SA, headquartered in Paris and founded in 2006, is a biotechnology firm dedicated to developing therapeutics for age‑related degenerative conditions. The company is currently pursuing two clinical trials: one targeting sarcopenia and another addressing Duchenne muscular dystrophy. Additionally, Biophytis is advancing Macuneos into Phase I/IIa trials for treating age‑related macular degeneration and genetic retinopathy. Its product pipeline, coupled with ongoing clinical investigations, positions Biophytis as a potential contributor to the growing market for anti‑aging and rare‑disease therapies.
For further detail on the company’s initiatives, visit the official website at www.biophytis.com or consult the NYSE Euronext Paris listings.
